Abstract: The disclosed system may include a detachable capsule that includes a capsule-side capacitive plate. The system may also include a receiving antenna electrically connected to an antenna-side capacitive plate, and a capacitive sensor electrically connected to the capsule-side capacitive plate. The two plates may be coupled to each other and may transmit RF signals between them. The capacitive sensor may be configured to detect an amount of capacitance between the two capacitive plates. The system may also include an antenna matching tuner electrically connected to the capacitive sensor and to an antenna feed. Then, upon receiving capacitance measurements from the capacitive sensor, the antenna matching tuner may alter various parameters of the antenna feed including impedance matching parameters. Various other apparatuses and mobile wearable devices are also disclosed.

Abstract: A method and a wafer processing furnace for forming a doped polysilicon layer on a plurality of substrates is provided. In a preferred embodiment, the method comprises providing a plurality of substrates to a process chamber. It also comprises executing a deposition cycle comprising providing a silicon-containing precursor to the process chamber thereby depositing, on the plurality of substrates, an undoped silicon layer until a pre-determined thickness is reached and providing the process chamber with a flow of a dopant precursor gas without providing the silicon-containing precursor to the process chamber. The method also comprises performing a heat treatment process, thereby forming the doped polysilicon layer.

Abstract: Method of constructing a vault of a large storage tank for liquefied natural gas by first modeling the vault with a 3-D modeling software application, then partially building the vault with a framework and a first set of covering panels fixed on the framework where the panels do not touch each other, but leave a number of gaps between them, measuring the dimensions of the actual gaps between the panels using a 3-D scanner, producing a second set of panels according to the scanned dimensional data, and finally filled the gaps between the first set of panels with the second set of panels, which are much smaller than the first set of panels, making the building process earlier and more accurate, which are difficult issues in building large tanks for liquefied natural gas.

Abstract: Method of constructing a vault of a large storage tank for liquefied natural gas by first modeling the vault with a 3-D modeling software application, then partially building the vault with a framework and a first set of covering panels fixed on the framework where the panels do not touch each other, but leave a number of gaps between them, measuring the dimensions of the actual gaps between the panels using a 3-D scanner, producing a second set of panels according to the scanned dimensional data, and finally filled the gaps between the first set of panels with the second set of panels, which are much smaller than the first set of panels, making the building process earlier and more accurate, which are difficult issues in building large tanks for liquefied natural gas.

Abstract: Preparation and application of line leaf inula flower lactone A for treating myocarditis having a structure of The compound shows positive therapeutic activity against Coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone A prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d. When increased to 100 mg/kg/d, the line leaf inula flower lactone A shows positive therapeutic effect on EAM. Line leaf inula flower lactone A is used as the sole active ingredient and combined with a conventional pharmaceutical carrier in a drug for treating myocarditis, and the pharmaceutical composition may be in the form of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol.

Abstract: Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure of Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.

Abstract: Preparation and application of line leaf inula flower lactone A for treating myocarditis having a structure of The compound shows positive therapeutic activity against Coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone A prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d. When increased to 100 mg/kg/d, the line leaf inula flower lactone A shows positive therapeutic effect on EAM. Line leaf inula flower lactone A is used as the sole active ingredient and combined with a conventional pharmaceutical carrier in a drug for treating myocarditis, and the pharmaceutical composition may be in the form of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol.

Abstract: Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure of Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.

Abstract: A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound.

Abstract: A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound.

Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.

Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.

Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.

Abstract: A method for promoting differentiation of clonogenic neural stem cells (NSCs), comprising administering to a patient in the need of such promoting a coumarin compound represented by formula I or by formula II. The representative coumarin compounds include 7-hydroxycoumarin, daphnoretin, scopoletin, edgeworin, aesculetin and esculetin-6-?-D-glucopyranoside. The coumarin compounds showed significant activity of directing the differentiation of NSCs in pharmacological test and thereof could be used to prepare drugs to direct NSCs differentiated to oligodendrocyte progenitor cells (OPCs) for the treatment of demyelinating diseases or spinal cord injury. The drug could be a pure coumarin compound or a pharmaceutical composition comprising a therapeutical dose of a coumarin compound as active ingredients and a pharmaceutically-acceptable carrier. The content of the active ingredients in the pharmaceutical composition is between 0.1% and 99.5% by weight.

Abstract: A method for preparing dehydrocavidine, dehydroapocavidine and their respective composition is provided. The composition is first prepared by isolating and purifying the quaternary ammonium alkaloid components from the medicinal plant “Yan Huang Lian” (Corydalis saxicola Bunting) through the processes of solvent extraction, water-phase organic extraction, crystallization and recrystallization, and then drying to obtain said composition containing dehydrocavidine and dehydroapocavine. When necessary, the composition or their crude extracts can be separated by chromatography to obtain dehydrocavidine or dehydroapocavidine. Dehydrocavidine, dehydroapocavidine or their respective composition can be used in manufacturing medicines for treating viral hepatitis, hepatic injury, influenza, AIDS, tumors or arrhythmia.